Advertisement
Screener

SAB BIOTHERAPEUTICS, INC. (SABS) Graph

SABS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2020-12-31: Operating expenses $9.00K; Net income -$9.00K.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 2 month

Period endOperating expensesNet income
2020-12-31$9.00K-$9.00K

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$16.17M$23.38M(m)-$22.49M
2026-03-31(m)$13.40M$20.00M(m)-$18.87M
2025-12-31(m)$10.73M*$15.77M*(m)-$16.86M*
2025-09-30(m)$8.97M$12.68M(m)$45.45M
2025-06-30(m)$7.00M$9.73M(m)-$10.11M
2025-03-31(m)$7.66M$10.77M(m)-$5.20M
2024-09-30(m)$7.83M$11.31M(m)-$10.35M
2024-06-30$263.14K$6.82M$10.46M(m)-$7.34M
2024-03-31$944.58K$8.15M$12.34M(m)-$5.03M
2023-09-30$1.27M$4.02M$6.59M(m)-$5.10M
2023-06-30$85.52K$3.66M$6.56M$0.00-$6.88M
2023-03-31$581.10K$4.54M$7.98M$0.00-$7.35M
2022-09-30$3.59M$7.35M$11.40M(m)-$7.08M
2022-06-30$6.35M$8.58M$12.89M-$92.28K-$4.78M
2022-03-31$11.80M$13.32M$18.51M$92.28K$985.86K
2021-09-30$14.68M$15.07M$18.67M(m)-$4.06M
2021-06-30$18.21M$18.68M$21.08M(m)-$2.94M
2021-03-31$16.93M$12.78M$16.11M(m)$1.41M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$29.57M$43.38M(m)-$41.36M
2025-06-30(m)$14.65M$20.50M(m)-$15.31M
2024-06-30$1.21M$14.77M$22.80M(m)-$12.36M
2023-06-30$666.62K$8.20M$14.55M$0.00-$14.23M
2022-06-30$18.15M$21.95M$31.40M$0.00-$3.79M
2021-06-30$35.14M$31.47M$37.20M(m)-$1.53M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30(m)$23.62M$33.18M$30.13M
2024-09-30$1.21M$22.60M$34.11M-$22.71M
2023-09-30$1.93M$12.22M$21.14M-$19.34M
2022-09-30$21.74M$29.30M$42.80M-$10.87M
2021-09-30$49.82M$46.54M$55.87M-$5.59M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$0.00$34.35M$48.95M$0.00$13.27M
2024-12-31$1.32M$30.25M$44.23M$0.00-$34.11M
2023-12-31$2.24M$16.52M$40.31M$0.00-$42.19M
2022-12-31$23.90M$36.44M$52.82M$25.63K-$18.74M
2021-12-31$60.88M$57.18M$74.27M$0.00-$17.14M
2020-12-31$55.24M$27.91M$34.68M$0.00$20.12M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Ocugen, Inc. (OCGN)United States$0.343B-6.34
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05